Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5761-5769

  Nimmanapalli, Ramadevi ^a   O'Bryan, Erica ^a   Huang, Mei ^a   Bali, Purva ^a   Burnette, Pearlie Kay ^a   Loughran, Thomas ^a   Tepperberg, James ^b   Jove, Richard ^a   Bhalla, Kapil ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BCR ABL PROTEIN; CYTARABINE; HEAT SHOCK PROTEIN 70; IMATINIB; MESSENGER RNA; PROTEIN P185; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION;

BENZOQUINONES; BLAST CRISIS; CYTARABINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; K562 CELLS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID, CHRONIC; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; PYRIMIDINES; RIFABUTIN; SRC-FAMILY KINASES; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0037108879     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Thijsen, S. F., T., Schuurhuis, G. J., van Oostveen, J. W., and Ossenkoppele, G. J. Chronic myeloid leukemia from basics to bedside. Leukemia (Baltimore), 13: 1646-1674, 1999
2. Faded, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-172, 1999
3. Deininger, M., Goldman, J., and Melo, J. The molecular biology of chronic myeloid leukemia. Blood. 96: 3343-3356, 2000
4. Westbrook, C. A., Hooberman, A. L., Spino, C., Dodge, R. K., Larson, R. A., Davey, F., Wurster-Hill, D. H., Sobol, R. E., Schiffer, C., and Bloomfield, C. D. Clinical significance of the Bcr-Abl fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study. Blood, 80: 2983-2990, 1992
5. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood, 86: 1148-1158, 1995
6. Ray, S., Bullock, G., Nunez, G., Tang, C., Irado, A. M., Huang, Y., and Bhalla, K. Enforced expression of Bcl-xs induces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C-mediated differentiation and apoptosis. Cell Growth Differ., 7: 1617-1623, 1996
7. Amarante-Mendes, G., Kim, C., Liu, L., Huang, Y., Perkins, C., Green, D., and Bhalla, K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood, 91: 1700-1705, 1998
8. Sillaber, C., Gesbert, F., Frank, D., Sattler, M., and Griffin, J. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood, 95: 2118-2125, 2000
9. L gene through STAT5. Blood, 96: 2269-2276, 2000
10. Datta, S. R., Brunet, A., and Greenberg, M. E. Cellular survival: A play in three Akts. Genes Dev., 13: 2905-2927, 1999
11. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J., Trotta, R., Wlodarski, P., Perrito, D., Chan, T., Wasik, M., Tsichlis, P., and Calabretta, B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J., 16: 6151-6161, 1997
12. Neshat, M., Raitano, A., Wang, H., Reed, J., and Sawyers, C. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol., 20: 1179-1186, 2000
13. Reuter, J., Reuther, G. W., Cortez, D., and Pendergast, A. M. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev., 12: 968-981, 1998
14. Hamdane, M., David-Cordonnier M-H., and D'Halluin, J. C. Activation of p65 NF-κB protein by p210 BCR-ABL in a myeloid cell line (p210 BCR-ABL activates p65 NF-κB). Oncogene, 15: 2267-2275, 1997
15. Wang, C. Y., Mayo, M. W., Komeluk, R. G., et al. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Wash. DC), 281: 1680-1683, 1998
16. Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perrotti, D., Hoser, G., Kawiak, J., Majewski, M., Christensen, L., Iozzo, R. V., and Calabretta, B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J. Natl. Cancer Inst. (Bethesda), 89: 124-133, 1997
17. Svingen, P., Tefferi, A., Kottke, T., Kaur, G., Narayanan, V., Sausville, E., and Kaufmann, S. Effects of bcr-abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin. Cancer Res., 6: 237-249, 2000
18. Cobaleda, C., and Sanchez-Garcia, I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment. Blood, 95: 731-737, 2000
19. Buchdunger, E., Zimmerman, J., Mett, H., Meyer, T., Muller, M., Druker, B., and Lydon, N. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996
20. Heinrich, M., Griffith, D., Druker, B., Wait, C., Ott, K., and Zigler, A. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood, 96: 925-932, 2000
21. Druker, B. J., Tamura, S., Buchdunger, E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996
22. Deininger, M. W. N., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997
23. Fang, G., Kim, C., Perkins, C., Ramadevi, N., Winton, E., Wittman, S., and Bhalla, K. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 96: 2246-2253, 2000
24. Thiesing, J., Ohno-Jones, S., Kolibaba, K., and Druker, B. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood, 96: 3195-3199, 2000
25. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sata, Y., Honma, Y., and Furukawa, Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 97: 1999-2007, 2001
26. Ashkenazi, A., and Dixit, V. Death receptors: Signaling and modulation. Science (Wash. DC), 281: 1305-1308, 1998
27. Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E., and Bhalla, K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L (TRAIL)-induced apoptosis of human acute leukemia cells. Blood, 96: 3900-3906, 2000
28. Ramadevi, N., Porosnicu, M., Nguyen, D., Worthington, E., O'Bryan, E., Perkins, C., and Bhalla, K. Co-treatment with STI-571 enhances TNF-α-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin. Cancer Res., 7: 350-357, 2001
29. Kraker, A., Hartl, B., Amar, A., Barvian, M., Showalter, H. D., and Moore, C. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol., 60: 885-898, 2000
30. Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res., 60: 3127-3131, 2000
31. Nimmanapalli, R., O'Bryan, E., and Bhalla, K. Geldanamycin and it analogue 17-allylamino-17-demothoxygeldanamycin (17-AAG) lowers Bcr-Abl level and induces apoptosis and differentiation of Bcr-Abl positive human leukemic blasts. Cancer Res., 61: 1799-1804, 2001
32. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., and Druker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002
33. Druker, B., Sawyers, C., Kantarjian, H., Resta, D., Reese, S., Ford, J., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chronosome. N. Engl. J. Med., 344: 1038-1042, 2001
34. Savage, D., and Antman, K. Imatinib mesylate: A new oral targeted therapy. N. Engl. J. Med., 346: 683-693, 2002
35. le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Cambacorti-Passerini, C. Induction of resistance to the Abelson inhibitor STI-571 in human leukemic cells through gene amplification. Blood, 95: 1758-1766, 2000
36. Weisberg, E., and Griffin, J. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI-571 in BCR/ABL-transforrned hematopoietic cell lines. Blood, 95: 3498-3505, 2000
37. Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood, 96: 1070-1079, 2000
38. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F., and D'Incalci, M. Role of α1 acid glycoprotein in the in vivo resistance of human Bcr-Abl+ leukemic cells to the Abl inhibitor STI571. J. Natl. Cancer Inst. (Bethesda), 92: 1641-1650, 2000
39. Gorre, M., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001
40. Barthe, C., Cony-Makhoul, P., Melo, J., Reiffers, J., and Mahon, F. X. Roots of clinical resistance to STI571 therapy. Science (Wash. DC), 293: 2163a, 2001
41. Huang, Y., Ibrado, A. M., Nuñez, G., Reed, J. C., Bullock, G., Ray, S., Tang, C., and Bhalla, K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia (Baltimore), 11: 253-257, 1997
42. Ibrado, A. M, Kim, C. N., and Bhalla, K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome c and caspase-3 activity during Taxol-induced apoptosis. Leukemia (Baltimore), 12: 1930-1936, 1998
43. Perkins, C., Kim, C. N., Fang, G., and Bhalla, K. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res., 58: 4561-4566, 1998
44. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., de Groot, R. P., and Jove, R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol., 18: 2545-2552, 1998
45. Preudhomme, C., Revillon, F., Merlat, A., Hornez, L., Roumier, C., Duflos-Grardel, N., Jouet, J. P., Cosson, A., Peyrat, J. P., and Fenaux, P. Detection of Bcr-Abl transcripts in chronic myeloid leukemia (CML) using a "real time" quantitative RT-PCR assay. Leukemia (Baltimore), 13: 957-964, 1999
46. Perkins, C., Kim, N. K., Fang, G., and Bhalla, K. Arsenic induces apoptosis of multi-drug resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2 or Bcl-xL. Blood, 95: 1014-1022, 2000
47. Saleh, A., Srinivasula, S., Balkir, L., Robbins, P., and Alnemri, E. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol., 2: 476-483, 2000
48. Jaattela, M., Wissing, D., Kokholm, K., Kallunki, T., and Egeblad, M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J., 17, 6124-6134, 1998
49. Dent, P., and Grant, S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action. Clin. Cancer Res., 7: 775-783, 2001
50. Donato, N., Wu, J., Albitar, M., Arlinghaus, R., Kantarjian, H., and Talpaz, M. Multiple resistance mechanisms identified through studies of cell lines derived from chronic myelogenous leukemia patients progressing on STI-571 therapy. Blood, 98: 3206, 2001
51. Donato, N., Wu, J., Gallick, G., Arlinghaus, R., and Talpaz, M. A dominant role for LYN kinase in K562 cells selected for resistance to STI-571. Blood, 98: 3487, 2001